<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392470</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000512816</org_study_id>
    <secondary_id>CHUV-CEPO-CORCC-204-5</secondary_id>
    <secondary_id>EU-20645</secondary_id>
    <secondary_id>PFIZER-CHUV-CAPO-CARK-204-5</secondary_id>
    <secondary_id>MERCK-CHUV-CAPO-CARK-204-5</secondary_id>
    <nct_id>NCT00392470</nct_id>
  </id_info>
  <brief_title>Radiation Therapy, Irinotecan, and Cetuximab in Treating Patients Who Are Undergoing Surgery for Stage III or Stage IV Rectal Cancer</brief_title>
  <official_title>Neoadjuvant Conformal Radiotherapy and Concomitant CPT-11 and EGFR Inhibition With Cetuximab in Patients With Rectal Cancer Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to&#xD;
      the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in&#xD;
      chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells,&#xD;
      either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as&#xD;
      cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to&#xD;
      grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances&#xD;
      to them. Giving radiation therapy together with irinotecan and cetuximab before surgery may&#xD;
      make the tumor smaller and reduce the amount of normal tissue that needs to be removed.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of irinotecan when&#xD;
      given together with cetuximab and radiation therapy in treating patients who are undergoing&#xD;
      surgery for stage III or stage IV rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the toxicity of irinotecan hydrochloride and cetuximab in patients with stage&#xD;
           III or IV rectal cancer undergoing conformal or intensity-modulated radiotherapy.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the rate of pathologic response and histological degree of tumor regression in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the complete resection rate (R0) in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the sphincter preservation rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the 30-day postoperative complication rate in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the local and distant relapse rate and site of disease failure in patients&#xD;
           treated with this regimen.&#xD;
&#xD;
        -  Estimate the predictive value of fludeoxyglucose F 18 positron emission tomography/CT&#xD;
           scan for treatment response compared to endoscopic ultrasonography (EUS), CT scan, and&#xD;
           MRI in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the late toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Determine the clinical (radiological) tumor response (i.e., MRI, CT scan, EUS) in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of irinotecan hydrochloride.&#xD;
&#xD;
      Patients receive cetuximab IV over 1-2 hours on days 1, 8, 15, 22, 29, 36, and 43 followed by&#xD;
      irinotecan hydrochloride IV over 30 minutes on days 1, 8, 15, 22, and 29. Patients also&#xD;
      undergo conformal radiotherapy or intensity-modulated radiotherapy on days 1-5 for 5 weeks.&#xD;
      Patients undergo radical surgery 3-4 weeks after completion of neoadjuvant therapy.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of irinotecan hydrochloride until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for at least 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Radiological (clinical) tumor response before surgery</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathologic response rate and histological degree of tumor regression as measured by Mandard TRG score</measure>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Colorectal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-dimensional conformal radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the rectum&#xD;
&#xD;
               -  T3-4 and/or N+ (stage IIIB, IIIC, or IV disease)&#xD;
&#xD;
          -  Liver or lung metastasis allowed&#xD;
&#xD;
          -  No recurrent disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0 or 1&#xD;
&#xD;
          -  Hematologic, liver, and renal function normal&#xD;
&#xD;
          -  Considered fit for chemotherapy, radiotherapy, and surgery&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No symptomatic heart disease or myocardial infarction during the past 6 months&#xD;
&#xD;
          -  No chronic inflammatory bowel disease&#xD;
&#xD;
          -  No malignant tumor during the past 5 years except for completely surgically resected&#xD;
             carcinoma of the cervix or squamous cell carcinoma of the skin&#xD;
&#xD;
          -  No other concurrent malignant tumor&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy or radiotherapy for rectal cancer&#xD;
&#xD;
          -  No prior radiotherapy to the pelvis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Montemurro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Moosmann, MD, PhD</last_name>
      <phone>41-62-838-6051</phone>
      <email>peter.moosmann@ksa.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Ludwig de Recherche sur le Cancer</name>
      <address>
        <city>Epalinges</city>
        <zip>1066</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Curzio Ruegg, MD</last_name>
      <phone>44-412-1692-5853</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Montemurro, MD</last_name>
      <phone>41-21-314-4530</phone>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <last_update_submitted>May 24, 2011</last_update_submitted>
  <last_update_submitted_qc>May 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2011</last_update_posted>
  <keyword>adenocarcinoma of the rectum</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

